Section 1: Introduction -- The Tablet Taken the Wrong Way for Five Years

A 68-year-old woman in Trinidad has been on alendronate 70 mg weekly for five years. At every dispensing, she collects the tablets and takes them at the same time as her other morning medications -- with a glass of juice, sitting in a chair, then lying down for a rest while they settle.

She has had two vertebral fractures in three years. Her bone mineral density has not improved. Her clinician increases the dose.

The dose is not the problem. Bisphosphonate absorption from the gastrointestinal tract is extremely poor even under optimal conditions -- approximately 1-3% of the oral dose is absorbed. Under the conditions this patient is using -- with juice (which chelates the drug), with food, lying down after ingestion -- absorption is negligible. She has been taking a placebo-equivalent dose for five years.

Bisphosphonate prescribing has a single non-negotiable administration rule that is incompletely communicated and infrequently followed: take the tablet on waking, swallow with a full glass of plain water only, remain upright and do not eat, drink, or take any other medication for 30 minutes. Every element of this rule has a pharmacological basis, and violation of any element substantially reduces absorption.

Caribbean osteoporosis prescribing has four additional challenges this report addresses:

Vitamin D deficiency in sunny climates. The Caribbean receives abundant sunshine. Caribbean patients of darker skin phototypes require longer ultraviolet exposure to produce equivalent vitamin D, and many spend limited time outdoors with skin exposed due to cultural practices, protective clothing, and indoor working. Vitamin D deficiency is common and frequently unrecognised. Without adequate vitamin D, bisphosphonate efficacy is substantially reduced.

Calcium and drug interactions. Calcium supplements are widely taken in the Caribbean and are prescribed alongside bisphosphonates. Calcium must be separated from bisphosphonates by at least 30 minutes -- ideally taken at a different time of day. Many patients take both together.

Duration dilemmas. Bisphosphonates accumulate in bone and continue to provide protection for years after discontinuation. The benefit of treatment beyond five years must be weighed against the risk of atypical femoral fractures and osteonecrosis of the jaw. Planned treatment breaks ("drug holidays") should be discussed at the five-year mark.

Falls prevention. Osteoporosis fractures are not purely a bone density problem. The most important factor in fracture risk in older adults is falling. Falls prevention -- medication review, balance and strength training, vision assessment, environmental modification -- must accompany pharmacological bone treatment.

Section 2: Bisphosphonates -- The Administration Rule

2.1 Why the administration rule exists

Bisphosphonates (alendronate, risedronate, ibandronate, zoledronic acid) are poorly absorbed orally. Their oral bioavailability is 1-3% under optimal conditions. This small absorption window is further reduced by anything that: - Changes gastric pH (antacids, PPIs, calcium, food) - Chelates the drug (calcium, magnesium, iron, aluminium, divalent cations) - Reduces oesophageal and gastric transit time (lying down)

The oesophageal transit concern is equally important: bisphosphonates are corrosive to the oesophageal mucosa. If the tablet dissolves in the oesophagus rather than reaching the stomach -- from insufficient water, lying down, or pre-existing oesophageal pathology -- it can cause oesophagitis, oesophageal ulceration, and rarely oesophageal stricture.

2.2 The rule, point by point

2.3 Oral bisphosphonates available in Caribbean practice

2.4 Intravenous zoledronic acid -- the solution to oral administration failure

When patients cannot follow the oral administration rules (severe GORD, oesophageal pathology, cognitive impairment, inability to remain upright), or where oral adherence has been poor, intravenous zoledronic acid 5 mg given once yearly as an infusion over 15 minutes is the appropriate alternative.

The HORIZON trial demonstrated that annual IV zoledronic acid reduces hip fracture risk by 41% and vertebral fracture risk by 70% in postmenopausal women with osteoporosis.

Post-infusion: flu-like symptoms (fever, myalgia, headache, arthralgia) occur in approximately 30% of patients within 24-72 hours of the first infusion. Paracetamol covers this adequately. Hydration before and after the infusion reduces the risk. Subsequent annual infusions have lower rates of post-infusion symptoms.

Renal caution: Zoledronic acid is renally cleared. It is contraindicated when CrCl is below 35 mL/min (Report 2).

Section 3: Vitamin D and Calcium -- The Essential Adjuncts

3.1 Vitamin D in the Caribbean

Vitamin D is produced in the skin on exposure to ultraviolet B radiation. The assumption that Caribbean populations are vitamin D replete due to sun exposure is not supported by the evidence. Studies across Barbados, Jamaica, and Trinidad report vitamin D deficiency (25-hydroxyvitamin D below 50 nmol/L) in 30-70% of community-dwelling adults, with higher rates in darker skin phototypes and in older adults.

Reasons for vitamin D deficiency in the Caribbean: - Darker skin phototypes require 3-6 times longer sun exposure to produce the same vitamin D as lighter phototypes - Protective clothing, sunscreen use, and indoor working reduce effective UV exposure - Traditional Caribbean diets contain limited dietary vitamin D sources (oily fish, fortified dairy) - Obesity impairs vitamin D availability (sequestration in fat tissue)

Clinical implication: All patients initiating bisphosphonate therapy should have serum 25-hydroxyvitamin D measured before or at initiation. Deficiency must be corrected before or alongside bisphosphonate therapy, as bisphosphonates cannot function effectively in a vitamin D-deficient skeleton.

3.2 Vitamin D supplementation

3.3 Calcium

Calcium 1000-1200 mg/day total intake (dietary plus supplemental) is recommended for patients on bisphosphonate therapy. Dietary calcium should be assessed first -- dairy products, tinned fish with bones, leafy greens. Supplemental calcium is only required to make up the deficit.

Calcium supplement timing: Must be taken at least 2 hours after bisphosphonate and ideally at a different time of day. Many patients take both with breakfast -- this negates bisphosphonate absorption.

Calcium and cardiovascular risk: There is a contested body of literature suggesting that calcium supplementation (not dietary calcium) may modestly increase cardiovascular risk, particularly in men. The absolute risk is small and the evidence is inconsistent, but it reinforces the principle of dietary calcium first, supplemental calcium to make up the deficit only.

Section 4: Who Needs Treatment -- Risk Assessment

4.1 Risk assessment tools

Fracture risk should be assessed before initiating bisphosphonate therapy. The FRAX tool (WHO Fracture Risk Assessment Tool) estimates 10-year fracture probability using clinical risk factors with or without bone mineral density.

Key risk factors captured in FRAX: age, sex, BMI, prior fragility fracture, parental hip fracture, smoking, glucocorticoid use, rheumatoid arthritis, secondary osteoporosis, alcohol consumption.

Caribbean-specific note: FRAX was developed predominantly in European and some Asian populations. Its calibration for Caribbean populations of African descent is uncertain. Caribbean patients of African descent have higher bone density at any given age than those of European ancestry -- but they also have higher rates of diabetes, hypertension, and glucocorticoid use (for autoimmune disease, asthma, and skin conditions), all of which increase fracture risk independently. Clinical judgement alongside FRAX is necessary.

4.2 Who to treat

4.3 Glucocorticoid-induced osteoporosis

Glucocorticoids reduce bone mineral density rapidly -- 6-12% in the first year of treatment, then more slowly. All patients starting systemic glucocorticoids at the above dose and duration should receive: - Bisphosphonate (alendronate 70 mg weekly is first-line) - Calcium 1000-1200 mg/day - Vitamin D 800-1000 IU/day

This is a significantly under-implemented intervention in Caribbean practice. Patients on long-term steroids for rheumatoid arthritis, lupus, asthma, and inflammatory bowel disease frequently receive no bone protection.

Section 5: Adverse Effects and Duration

5.1 Oesophageal adverse effects

Upper GI symptoms -- heartburn, dyspepsia, oesophagitis -- are the most common reason for bisphosphonate discontinuation. They are largely preventable by correct administration (see Section 2). If they persist despite correct technique, switch to risedronate (lower GI adverse effect rate), monthly dosing, or IV zoledronic acid.

5.2 Osteonecrosis of the jaw (ONJ)

Osteonecrosis of the jaw is a rare but serious complication characterised by exposed or necrotic bone in the jaw lasting more than 8 weeks. It is more commonly associated with IV bisphosphonates at high oncological doses (used for bone metastases) than with the lower doses used for osteoporosis. The risk with oral bisphosphonates for osteoporosis is very low -- estimated at 1 in 10,000 to 1 in 100,000 patient-years.

Dental care: Patients on bisphosphonates should be encouraged to maintain good oral hygiene and attend for regular dental review. Major dental procedures (tooth extraction, implants) in a patient on long-term bisphosphonate require discussion with both prescriber and dentist. Routine dental procedures carry minimal risk.

5.3 Atypical femoral fractures

Prolonged bisphosphonate use (typically beyond 5 years) is associated with an increased risk of atypical subtrochanteric femoral fractures -- stress fractures through the femoral shaft with a characteristic radiographic appearance. The absolute risk is low but increases with duration. Patients should be counselled to report thigh or groin pain during bisphosphonate treatment.

5.4 Drug holidays

At the five-year mark of oral bisphosphonate therapy, the fracture risk should be reassessed. Bisphosphonates accumulate in bone and continue to provide protection after discontinuation. For patients at lower residual risk (T-score above -2.5, no prior hip fracture), a drug holiday of 2-3 years may be appropriate. Patients at higher risk (T-score below -2.5, prior hip fracture) should continue treatment or switch to an alternative agent.

Section 6: Other Osteoporosis Drugs

6.1 Denosumab

Denosumab is a RANK-L inhibitor given as a subcutaneous injection every 6 months. It is effective and does not require the oral administration restrictions of bisphosphonates.

Critical caution: Denosumab must not be stopped abruptly. Unlike bisphosphonates, which accumulate in bone, denosumab's effect reverses rapidly on cessation. Bone mineral density falls sharply and multiple vertebral fractures can occur within months of stopping. If denosumab is to be discontinued, transition to a bisphosphonate is required before stopping.

6.2 Hormone replacement therapy (HRT)

HRT maintains bone density effectively during use and reduces fracture risk. It is a reasonable option in younger postmenopausal women (under 60) where osteoporosis treatment is needed alongside menopausal symptom management. The cardiovascular, thromboembolic, and breast cancer risks of HRT (Report 5) must be weighed against the bone benefit for each patient.

6.3 Raloxifene

Selective oestrogen receptor modulator (SERM). Reduces vertebral fracture risk. Does not reduce hip fracture risk. Increases DVT and pulmonary embolism risk. Reduces breast cancer risk. An option in younger postmenopausal women who cannot tolerate bisphosphonates and where hip fracture risk is not the primary concern.

Section 7: The Osteoporosis Prescribing Checklist

Section 8: About ElesRx

ElesRx flags calcium supplement co-administration with bisphosphonates when both appear in the same medication list without documented separation, and identifies patients on long-term glucocorticoids who have not been prescribed bone protection. The system also flags zoledronic acid dosing in patients with CrCl below 35 mL/min.

The tool is available at elesrx.com. ElesRx is a product of PIPPS Smart Apps, a division of J.C. Epiphany Limited (Jamaica, est. 1998).

Section 9: Methodology and References

9.1 Data sources

Osteoporosis prescribing data is drawn from the ElesRx clinical database, DailyMed, the European Medicines Agency, the Royal Osteoporosis Society (UK) guidelines, and the American Society for Bone and Mineral Research clinical guidelines.

9.2 Limitations

Teriparatide (anabolic bone therapy), romosozumab, and specialist-level management of severe or secondary osteoporosis are beyond this report's primary scope. DEXA scanning interpretation and FRAX calculation are referenced for clinical context; detailed instruction is not provided here.

9.3 Author and conflict of interest disclosure

This report was authored by Juliet Duncan, BPharm, founder of J.C. Epiphany Limited and developer of ElesRx. The author has a commercial interest in ElesRx. This report is published without an access gate as a contribution to Caribbean clinical education. No external funding was received.

9.4 Citation

Duncan J. The Osteoporosis Report: Bisphosphonates, Bone Health, and the Administration Rule That Is Never Followed. ElesRx Clinical Reports, Report 22. Prepared June 2026. Published 2027 at elesrx.com/reports/osteoporosis-report/. J.C. Epiphany Limited, Jamaica.

References

1. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment (FLEX trial). JAMA. 2006;296(24):2927-2938. doi:10.1001/jama.296.24.2927

2. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture (HORIZON). N Engl J Med. 2007;357(18):1799-1809. doi:10.1056/NEJMoa074941

3. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract. 2020;26(Suppl 1):1-46. doi:10.4158/GL-2020-0524SUPPL

4. Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment. J Bone Miner Res. 2016;31(1):16-35. doi:10.1002/jbmr.2708

5. Reid IR, Bristow SM, Bolland MJ. Calcium supplements: benefits and risks. J Intern Med. 2015;278(4):354-368. doi:10.1111/joim.12394